Skip to main content

Table 1 The baseline characteristics and HP infection status, serum PG test of gastric cancer and controls

From: Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: A monocentric cohort study in China

  Gastric cancer (n = 72) CAG (n = 61) CNAG (n = 27) Healthy control (n = 37)
Age(years, mean ± SD) 61.7±1.4ζ 56.7±1.4 48.1±2.8 56.7±2.8
Male/Female ratio 1.23 0.91 0.5 1.31
Histological type     
  Intestinal type 25(34.7%)    
  Diffuse type 47(65.3%)    
TNM stage     
  Early gastric cancer 16(22.2%)    
  Advanced gastric cancer 56(77.8%)    
HP infection status     
  HP positive 48(66.7%) 30(49.2%) 14(51.8%) 18(48%)
PG test     
  PG I (ng/ml) 76.91±4.78* 72.02±5.48 79.64±5.74 84.52±4.44
  PG II (ng/ml) 25.10±2.35** 19.44±1.27 18.27±1.93 14.39±1.12
  PG I/II ratio 3.91±0.29ξ 3.99±0.24 5.84±0.72 7.18±0.69
  1. ζ: No difference between gastric cancer and healthy group (P = 0.08); gastric cancer vs CAG P = 0.0179; gastric cancer vs CNAG, P < 0.001.
  2. *: No difference between cancer group and CAG, CNAG and healthy group.
  3. **: Gastric cancer vs. CAG, P = 0.0459; gastric cancer vs. CNAG, P = 0.0927; Gastric cancer vs. healthy, P = 0.002.
  4. ξ: Gastric cancer vs. CAG, P = 0.8485; gastric cancer vs. CNAG, P = 0.0038; gastric cancer vs. healthy, P < 0.0001.